BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Loyola University Medical Center Business Wire SALT LAKE CITY -- December 17, 2013 BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that Loyola University Medical Center (LUMC) in Maywood, Illinois has purchased a BSD-500 Hyperthermia System (BSD-500). Loyola University Medical Center (LUMC) is the core of the Loyola University Health System and one of the nation’s leading academic medical centers. In the U.S. News 2013-14 hospital rankings, Loyola's Cancer program was rated among the top 25 percent of hospitals in cancer treatment. LUMC is nationally recognized for providing technologically advanced treatments and for promoting patient safety. The purchase of the BSD-500 by this prestigious medical center is further evidence of the growing use of hyperthermia therapy in the United States and will increase the number of patients who will have access to innovative hyperthermia treatment. “Hyperthermia has been shown to be an effective adjuvant therapy for several types of cancers. It offers patients additional therapy options in their fight against cancer,” stated Dr. William Small Jr., Professor and Department Chairperson, Radiation Oncology, at LUMC. “I am excited to be able to offer this treatment modality here at Loyola University Medical Center and to continue to participate in research on the efficacy of this treatment option in additional types of cancers.” About Loyola University Medical Center Radiation Oncology Department The Radiation Oncology department at LUMC offers a full line of sophisticated radiation oncology treatment modalities, including unfractionated and fractionated stereotactic radiosurgery, external beam, rapid arc, image-guided radiotherapy, intensity-modulated radiation therapy, high-dose-rate and low-dose-rate brachytherapy, total body irradiation, electron beam, prostate seed implant, and intra-operative radiotherapy (IORT). Consistent with its education and research mission, the department is actively engaged in ongoing research, including innovative investigator initiated and cooperative group trials, translational, physics and basic science research. The department, working in tandem with the other Cancer Service Line specialists at Loyola, provides an integrated approach to providing both treatment and support services to patients. About the BSD-500 Hyperthermia System The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s MicroThermX microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information. Contact: BSD Medical Corporation William (Bill) S. Barth, 801-972-5555 fax: 801-972-5930 email@example.com
BSD Medical Announces Purchase of BSD-500 Hyperthermia System by Loyola University Medical Center
Press spacebar to pause and continue. Press esc to stop.